BS_HZRM07TW
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 30.814717477003942
- age_years
- 2.827
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- E2F_TARGETS+0.343
- MYC_TARGETS_V1+0.336
- DNA_REPAIR+0.306
- G2M_CHECKPOINT+0.270
- SPERMATOGENESIS+0.227
- PANCREAS_BETA_CELLS+0.151
- WNT_BETA_CATENIN_SIGNALING+0.030
- KRAS_SIGNALING_DN+0.024
- OXIDATIVE_PHOSPHORYLATION+0.016
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.586
- INTERFERON_GAMMA_RESPONSE-0.517
- PROTEIN_SECRETION-0.439
- TNFA_SIGNALING_VIA_NFKB-0.409
- ANDROGEN_RESPONSE-0.407
- INFLAMMATORY_RESPONSE-0.400
- BILE_ACID_METABOLISM-0.395
- CHOLESTEROL_HOMEOSTASIS-0.376
- IL6_JAK_STAT3_SIGNALING-0.372
- ANGIOGENESIS-0.344
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_V9HVBBDW | medulloblastoma | — | 0.952 |
| 2 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.947 |
| 3 | BS_E3BAT4C1 | medulloblastoma | — | 0.945 |
| 4 | BS_9PB3XH5D | medulloblastoma | — | 0.945 |
| 5 | BS_ZXYDSBM9 | medulloblastoma | — | 0.940 |
| 6 | BS_09Z7TC35 | medulloblastoma | — | 0.939 |
| 7 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.939 |
| 8 | BS_GE2RVZE6 | medulloblastoma | — | 0.937 |
| 9 | BS_Z45HD492 | medulloblastoma | — | 0.936 |
| 10 | s_150324_3a | EPN | Posterior Fossa EPN | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.343 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.336 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.306 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.227 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.151 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.024 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.016 | Remibrutinib | — uncovered |